{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-010658","form_type":"8-K","ticker":"MTVA","cik":"0001638287","company_name":"MetaVia Inc.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.539508+00:00","generated_at":"2026-05-17T17:40:18.538524+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"MetaVia Q2 net loss $4.0M; cash $17.6M; DA-1726 48mg data expected Q4 2025","bullets":["Net loss $4.0M ($0.26/sh) vs $10.1M ($1.85/sh) in Q2 2024; R&D expenses fell to $2.3M from $8.1M.","Cash $17.6M as of June 30, 2025, expected to fund operations into 2026.","Dosed first patient in 8-week 48mg MAD cohort of DA-1726 for obesity; top-line data due Q4 2025.","Signed AI collaboration with Syntekabio to identify new indications for DA-1241 beyond MASH.","Closed $10.0M private placement in May 2025 with Dong-A ST and Dong-A Socio Holdings."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-010658","json":"https://secwatch.observer/filing/0001558370-25-010658.json","markdown":"https://secwatch.observer/filing/0001558370-25-010658.md","text":"https://secwatch.observer/filing/0001558370-25-010658.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638287/000155837025010658/0001558370-25-010658-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638287/000155837025010658/mtva-20250807x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:40:18.538524+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}